Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
The initiative, funded entirely under the company’s CSR programme, is expected to reach over a million lives
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
This partnership represents a systemic shift from awareness to large-scale action for 57 lakh children
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpoints
The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns
Subscribe To Our Newsletter & Stay Updated
